International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

UCB’s BIMZELX® Receives FDA Approval for Moderate to Severe Plaque Psoriasis

UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the United States Food and Drug Administration (FDA). Notably, it is the first and only IL-17A and IL-17F inhibitor approved for treating adults with moderate to severe plaque psoriasis.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

New IPC Guidelines on Generalized Pustular Psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Introducing our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.